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HemifusionThe membrane-spanning domain (MSD) of human immunodeﬁciency virus type I (HIV-1) envelope
glycoprotein (Env) is critical for its biological activity. Initial studies have deﬁned an almost invariant “core”
structure in the MSD and demonstrated that it is crucial for anchoring Env in the membrane and virus entry.
We show here that amino acid substitutions in the MSD “core” do not inﬂuence speciﬁc virus–cell
attachment, nor CD4 receptor and CXCR4 coreceptor recognition by Env. However, substitutions within the
MSD “core” delayed the kinetics and reduced the efﬁciency of cell–cell fusion mediated by Env. Although we
observed no evidence that membrane fusion mediated by the MSD core mutants was arrested at a
hemifusion stage, impaired Env fusogenicity was correlated with minor conformational changes in the V2,
C1, and C5 regions in gp120 and the immunodominant loop in gp41. These changes could delay initiation of
the conformational changes required in the fusion process.University, 954 Gatewood Rd,
316.
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Human immunodeﬁciency virus type I (HIV-1) infection is
initiated by fusion of the viral membrane with that of the target
cell and is mediated by the viral envelope glycoprotein (Env). On the
virus surface, a trimer, composed of three non-covalently linked
dimers of gp120, the receptor-binding surface (SU) component, and
gp41, the membrane-spanning, trans-membrane (TM) component,
forms the functional Env complex (Eckert and Kim, 2001; Moore et
al., 1990; Willey and Martin, 1993; Wyatt and Sodroski, 1998). The
gp120 and gp41 glycoproteins are synthesized as a precursor gp160
glycoprotein, which is encoded by the env gene. The gp160 precursor
is cotranslationally glycosylated and, following transport to the
trans-Golgi network, is cleaved into the mature products by a
member of the furin family of endoproteases (Wyatt and Sodroski,
1998). Mature Env proteins are transported to the plasma mem-
brane where they are rapidly endocytosed or incorporated into
virions (Byland et al., 2007; Rowell et al., 1995; Wilk et al., 1996).
The HIV-1 gp120 glycoprotein binds to the CD4 receptor and
chemokine coreceptors and consists of ﬁve conserved domains (C1–C5)
andﬁve variable domains (V1–V5) (Fig. 1A). Several studies suggest that
the C1 and C5 regions directly interact with the immunodominant loopin gp41 (Binley et al., 2000; Helseth et al., 1990; Ivey-Hoyle et al., 1991).
The C2 region is sequestered in the oligomeric structure and involved in
theoligomerization of gp120(Lemasson et al., 1995). Thebindingof CD4
toHIV-1 Env requiresmultiple conserved regions in gp120, includingC1
(Kropelin et al., 1998; Orloff et al., 1995), C3 (Howie et al., 1998, 1999),
and C4 (Morrison et al., 1995). A comparison of the sequence and
structural proﬁles of HIV-1 and SIV Env shows that theC2–V3–C3 region
is involved in the contact with chemokine receptors (Chen et al., 2005;
Shimizu and Gojobori, 2000). The V3 loop is a hyper variable disulﬁde-
bonded structure and is the major determinant of the tropism of HIV-1
virions (Hartley et al., 2005). The V1V2 region also inﬂuences HIV-1
cellular tropism, probably via an interaction with regions of the V3 loop
(Boyd et al., 1993; Koito et al., 1994). The V4 and V5 regions of gp120
may also be necessary for efﬁcient utilization of CXCR4 (Cho et al., 1998;
Labrosse et al., 2001). Moreover, the V1V2 and V3 regions have been
demonstrated to play a more important role when HIV-1 uses, in
addition to CCR5or CXCR4, other chemokine coreceptors such as CCR2b,
CCR3, STRL33, and APJ (Hoffman et al., 1998). In the dual tropic strain
89.6, the V3, V4, and V5 regions are involved in CCR5, CXCR4, and CCR3
utilization (Smyth et al., 1998).
The HIV-1 gp41 glycoprotein is the fusion machinery that mediates
virus–cell membrane fusion. When activated, the ectodomain of gp41
carries out the fusion function, while the membrane-spanning domain
and cytoplasmic domain are both important for its fusogenecity. The
ectodomain consists of a fusion peptide, two heptad repeats (HR1 and
HR2) with the immunodominant loop in between, and a membrane
Fig. 1. Kinetics of cell–cell fusion mediated by the Env. (A) A schematic structure of the
HIV-1 Env sequence (FP: fusion peptide; HR: heptad repeat; Loop: immunodominant
loop; MSD: membrane-spanning domain; LLP: Lentivirus lytic peptide). (B) Amino acid
sequences of HIV-1 MSDs. The consensus sequence of the HIV-1 MSD was generated by
the alignment of the Env MSD sequences of all M and N group HIV-1 isolates from the
Los Alamos HIV Sequences Database. The amino acid residues of the putative MSD
region are shown as upper case letters. The ﬂanking sequences of the HIV-1 MSD are
shown as lower case letters. The position of the MSD in the sequence of HIV-1 NL4-3 is
marked above the positively charged amino acid residues. The mutated portions of the
HIV-1 MSD are underlined. (C) Virus–cell attachment assay. Puriﬁed viruses were
coincubated with JC53BL cells at speciﬁc temperature for 2 h. Cells were then washed
three times in PBS and lysed in PBS containing 0.5% Triton X-100. The amount of p24 in
cell lysate was measured by p24 ELISA. The error bars represent the standard deviations
of three independent experiments. (D) Cell–cell fusion kinetics. 293T cells were
transfected with the proviral vector, pTN6-GFP, containing the MSD mutants. At 48 h
posttransfection, the transfected 293T cells were cocultured with the CMAC-blue-
loaded JC53BL indicator cells for speciﬁc times. Fused cells were observed and
quantitated by ﬂuorescent microscopy. For each mutant, at least 50 fusion events were
counted at each time point.
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contains signals for intracellular trafﬁcking of the Env and three lipid lytic
peptides (LLP1, LLP2, and LLP3) that play important roles in membrane
fusion (Comardelle et al., 1997; Miller et al., 1993; Tencza et al., 1995).
After the sequential binding of gp120 to the CD4 receptor and
chemokine coreceptors, changes in the conformation of gp120
activate the fusion competency of gp41. The N-terminal hydro-
phobic fusion peptide is released from a compact structure of gp41
and becomes associated with the outer monolayer of the target
membrane. Meanwhile, the ectodomains of the gp41 trimer are
rearranged into a six-helix bundle structure with the three HR1
segments in the center, forming a coiled-coil structure, and the
three HR2 segments on the outside, being tightly packed into the
hydrophobic grooves of the coiled-coil. This process brings
together the cell membrane associated fusion peptides with the
viral membrane-binding MSDs, and results in a close proximity
between the viral envelope and the cellular membrane, which is
necessary for virus–cell membrane fusion (Eckert and Kim, 2001;
White et al., 2008).
The membrane-spanning domain of Env is deﬁned as a stretch of
25 predominantly hydrophobic amino acids that spans residues
K681 to R705 (NL4-3). In the previous C-terminal truncation studies
of HIV-1 Env, we have demonstrated that the entire 25 amino acid
region is not required for the biological function of Env (Yue et al.,
2009). The 17 amino acid residues (fromK681 to A697) are sufﬁcient
for stably anchoring the truncated gp41 in the membrane and
mediating cell–cell fusion at a WT level. Serial small deletions (three
amino acid residues) in the region between R694 and R705 showed
normal cell–cell fusion, although larger deletions were detrimental,
suggesting that, with respect to the biological functions of the Env
glycoprotein, the length of this region is more important than its
amino acid conservation (Owens et al., 1991). From these data, we
have proposed a topology where the ﬂanking K681 and R694
residues “snorkel” in the membrane, and 12 amino acid residues
(from L682 to L693) form a hydrophobic core buried within the
membrane. Arginines 705 and 707 are located at the interface of
membrane and cytoplasm in this model (Yue et al., 2009).
The membrane-spanning domain, particularly within the “core”
region, is one of the most conserved sequences in Env. This argues
for a functional role of the MSD “core” in the biological activity of
the HIV-1 Env complexes. Recent studies of the MSD “core” region
have focused on the GXXXG motif in which the glycine residues are
the most conserved among all MSD residues. Statistical studies and
bacterial models suggested that the GXXXG motif probably
constructs a framework for the association of trans-membrane
helixes (Russ and Engelman, 2000; Senes et al., 2004, 2000).
Previously, we substituted all of the residues for leucine within the
HIV-1 MSD core, and then sequentially reintroduced the GGXXG
motif, and then two other highly conserved residues, F683 with
V687 (Shang et al., 2008). These studies showed that the speciﬁc
amino acid residues in the helical core of HIV-1 MSD are critical for
the fusogenicity of Env complexes and infectivity of HIV-1 virions.
The loss of infectivity correlated with impaired virus–cell entry.
However, these mutations in the MSD core did not inﬂuence the
biogenesis, intracellular transport and incorporation of Env
complexes.
In order to further understand the roles played by the more
conserved HIV-1 MSD core residues in virus–cell entry, we
attempted in the current study to deﬁne the mechanism by
which the MSD core mutants impact Env-mediated membrane
fusion. We show here that the amino acid composition of the MSD
core does not inﬂuence viral attachment to the cell surface or CD4
and CXCR4 recognition by HIV-1 Env. However, the cell–cell fusion
kinetics of the recovery-of-function mutants was delayed com-
pared to WT, and minor conformational changes in localized
regions of gp120 and gp41 were observed, suggesting that these
160 L. Shang, E. Hunter / Virology 404 (2010) 158–167changes might delay the triggering of the fusion process after
receptor-binding.Results
Previously, we used a recovery-of-function mutagenesis strategy
to deﬁne the roles of the speciﬁc amino acid residues within the 12-
amino acid MSD “core” in HIV-1 assembly and entry. The amino acid
sequences and nomenclature of the MSD “core”mutants are shown in
Fig. 1B. We have shown that the MSD “core” region of HIV-1 is critical
for its viral infectivity. Replacement of the conserved amino acid
residues with leucine residues blocked virus entry and subsequent
viral infection. Truncation of the cytoplasmic domain of the Env was
not able to rescue the impaired virus entry. In this study, we examined
the competence of these MSD “core” mutants at each step of virus
entry, in order to further understand the mechanistic basis for the
defects observed in this process.MSD mutants bind efﬁciently to target cells
Initially, we carried out a virus–cell attachment assay at low
temperatures (4 °C, 10 °C, and 25 °C for 2 h). Virions containing the
MSD mutant Envs adsorbed to the surface of JC53BL cells with the
same efﬁciency as those with WT Env (Fig. 1C), indicating that the
amino acid composition of theMSD “core” does not affect the ability of
HIV-1 Env to mediate a virus-speciﬁc binding to the cell surface.
Additionally, using an Env-free virus, we demonstrated that nonspe-
ciﬁc binding accounts for approximately 59% of virus–cell attachment
measured in this assay.MSD mutants showed delayed cell–cell fusion kinetics
In order to examine how the MSD “core” mutants inﬂuence the
fusogenicity of the HIV-1 Env, we measured the kinetics of Env-
mediated cell–cell fusion, using a ﬂuorescent marker transfer
system. The WT Env and MSD mutants were cloned into the pTN6-
GFP proviral vector, in which the nef gene is replaced by a GFP
reporter gene and then were transfected into 293T cells. In these
cells, the Env MSD mutants were transported to the cell surface as
efﬁciently as WT, since cells expressing WT and mutant Envs
demonstrated equivalent binding of the anti-gp120 monoclonal
antibody (MAb) 902 (data not shown). The transfected cells were
mixed with JC53BL cells, which were preloaded with the ﬂuorescent
dye CMAC-blue, and cell mixtures were cocultured for 0.5, 1, 2, 4, 6,
12, and 24 h. Fused cells ﬂuorescing with both colors were then
quantitated as a percent of total cells. As shown in the Fig. 1D, the
cell–cell fusion kinetics mediated by the Env MSD mutants was
slower than that of WT. After a lag period of approximately 1 h, WT
Env showed the highest initial rate of mediating cell–cell fusion
(28.87% cells per hour) between 1 and 2 h and a decreased rate
(35.3% of the initial rate) in the following 4 h. cell–cell fusion rates of
the mutants L12G and L12G2 were relatively constant during the
ﬁrst 12 h of incubation and were nearly 25% of the WT initial rate.
The L12 mutant exhibited a prolonged lag period of between 1 and
4 h prior to a linear increase in cell–cell fusion rate, which is
equivalent to those of the other two mutants. The WT Env reached
50% fusion at 4 h after cell mixing, while the mutants L12G and
L12G2were at 6 h, and the L12mutant was at 10 h. Moreover, at 12 h
after cell mixing, cell–cell fusion mediated by the Env mutants L12G
and L12G2 was equivalent to that of WT, while even at 24 h mutant
L12 showed only 84% of WT cell–cell fusogenicity. These data
indicated that the MSD “core”mutants impaired the rate of cell–cell
fusion by Env.CPZ treatment did not increase cell–cell fusion
The delayed cell–cell fusion kinetics suggested that the MSD “core”
mutants might have to overcome a higher energy barrier to mediate
membrane fusion than WT. In order to analyze whether the higher
energy barrier was created by a hemifusion intermediate, we treated
cells with 0.1 mMCPZ (chlorpromazine) for 30 seconds during the cell–
cell fusionmediatedby theEnv. CPZ speciﬁcally disrupts the lipid bilayer
structure in a hemifusion intermediate, which is formed by the two
inner layers of themembranes involved in the fusion, thereby enhancing
membrane fusion. An EnvmutantW610A (Bar andAlizon, 2004),which
was previously reported to form hemifusion intermediates during Env-
mediated cell–cell fusion, was used as a positive control for CPZ
treatment. As shown in Fig. 2A, although cell–cell fusogenicity of the Env
mutantW610A is much less thanWT (240 fold of EnvW610A) and Env
MSD mutants, CPZ treatment signiﬁcantly enhanced the Env-mediated
cell–cell fusion by 2-fold, indicating a break of the lipid bilayer structure
in hemifusion intermediates. However, CPZ treatment was unable to
promote a signiﬁcant increase in fusion for WT or any of the MSD
mutants (Fig. 2A). These results argue that the reduction in fusion
observed with the MSD “core” mutants is not due to fusion-arrest at a
hemifusion intermediate.
MSD “core” mutants can mediate full cell–cell fusion
In order to conﬁrm the absence of hemifusion intermediates
during membrane fusion mediated by the MSD mutants, we used
dual-color ﬂow cytometry analysis (Fig. 2B) and three-color micros-
copy (Fig. 2C) to examine cell–cell fusion mediated by the least
fusogenic mutant, L12. To measure Env-mediated lipid exchange
during cell–cell fusion, HeLa cells, which were transfected with NL4-3
proviral DNA and loaded with membrane dye DiO, were cocultured
with DiD-loaded HeLa P4 indicator cells. Similarly, cytoplasmic dye
CMFDA-green and CMAC-blue were used to stain HeLa cells and HeLa
P4 cells, respectively, to measure the exchange of cytoplasm during
cell–cell fusion. The DiO/DiD and green/blue double-positive cells
were examined by ﬂow cytometry. As shown in Fig. 2B, the Env-
mediated lipid exchange for the W610A mutant was 5-fold higher
than the corresponding mixture of cytoplasmic contents, consistent
with fusion being blocked at a hemifusion intermediate. In contrast,
equivalent levels of lipid and cytoplasmicmixingwere observed in the
assays of Env mutant L12, suggesting that fusion proceeded to
completion despite a reduction in fusion efﬁciency.
In the three-color microscopy experiment, Env-expressing HeLa
cells, whichwere loadedwith CMFDA-green, were coculturedwith DiI
(red) and CMAC-blue double-stained HeLa P4 indicator cells. Even
though cell–cell fusion induced by mutant L12 was only 11.1% of WT
after 3 h of coincubation (Fig. 1D), only complete cell–cell fusion
events, in which both the lipid dye and cytoplasmic dyes are mixed,
were observed (Fig. 2C). In contrast, hemifusion intermediates, in
which the lipid dye but not the cytoplasmic dyes are mixed, were
observed for mutant W610A (Fig. 2C). Similar studies, in which the
L12 mutant was expressed from the proviral vector pTN6-GFP,
demonstrated that those fusion pores which did form, were expanded
to a size that allowed at least 30 kDa molecules (GFP) to pass through
(data not shown).
High levels of CD4 receptors or CXCR4 coreceptors on the surface of
target cells cannot rescue the defects of the MSD “core” mutants in viral
infectivity
In order to determine whether the MSD core mutants exhibited
differential utilization of the CD4 receptor and CXCR4 coreceptor,
cell lines expressing different levels of these molecules were
employed. In the ﬁrst series of experiments, the HI-J, and RC-25
cell lines (Kabat), which express similar levels of CXCR4 but differ in
Fig. 2. Examination of hemifusion intermediates. (A) Cell–cell fusion mediated by Env. HeLa cells, which were transfected with proviral DNAs, were cocultured with HeLa P4
indicator cells for 12 h, and then mixed cells were treated with 0.1 mM CPZ for 30 s. After extensive wash, cells were incubated in complete DMEM for 10 h and then were subjected
to a β-Gal staining. The cell–cell fusogenicity of Env mutants were measured by counting the number of cells involved into syncytia (blue cells) per well (at least two different wells
were counted). (B) Flow cytometry analysis of cell-cell fusion. The proviral DNA-transfected HeLa cells were loaded with either membrane dye DiO or cytoplasmic dye Cell Tracker
Green, and then were cocultured with DiD-loaded or Cell Tracker Blue-loaded HeLa P4 indicator cells, respectively, for 6 h. The cell mixtures then were subjected to ﬂow cytometry
analysis. The double-positive cell populations are shown as percentage to WT. The error bars represent standard deviations of three independent experiments. (*, statistically
signiﬁcant) (C) Three color microscopy of cell–cell fusion mediated by the Env. HeLa cells, which were transfected with proviral DNAs and loaded with CMFDA-Green, were
cocultured with HeLa P4 indicator cells, which were double-stained with DiI (red) and CMAC-blue, for 3 h. Fused cells were observed by ﬂuorescent microscopy.
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WT and Env mutants were cloned into the pTN7 proviral vector, in
which the nef coding sequence is replaced by a renilla luciferase
reporter gene. Viruses produced by transfecting 293T cells with
these proviral DNAs were used to infect the two cell lines. At 48 h
postinfection, cells were subjected to a luciferase activity assay. For
each mutant, the viral infectivity in the HI-J cell lines was measured
as 100% and compared with that in the RC-25 cell line. As shown in
Fig. 3A, the higher level of surface CD4 enhanced virus infectivity of
both the WT and MSD mutants, with both the MSD mutants and the
WT exhibiting an approximately 2-fold increase in infectivity in the
HI-J cells.
To investigate sensitivity to changes in CXCR4, the HI-R and RC-
49 cells were utilized. These cells have equivalent levels of surfaceCD4, but a 6-fold difference in the surface level of CXCR4 (HI-R≫RC-
49). In contrast to changes in CD4, changes in the surface level of
CXCR4 had no effect on the infectivity of either theWT orMSD “core”
mutants (Fig. 3B). These results suggest that the amino acid
substitution in the MSD “core” does not affect CD4 or CXCR4
recognition by Env during viral entry.
MSD core mutants change the accessibility of epitopes to monoclonal
antibodies in the gp120 glycoprotein
In order to determine whether the MSD mutants alter the conforma-
tional integrity of gp120, wemeasured the binding of anti-gp120MAb to
the Env glycoprotein on the viral surface by a virus capture assay. Viruses
puriﬁedbyultracentrifugation through25% sucrosewere incubated in96-
Fig. 3. Sensitivity of MSD core mutants to the levels of CD4 and CXCR4 on cell surface.
The Env mutants were cloned into a proviral vector, pTN7, in which the nef coding
sequence was replaced by a renilla luciferase reporter gene. Viruses produced by
transfecting 293T cells with pTN7 constructs were used to infect HI- and RC- cell lines
(Kabat). Luciferase activities were measured 48 h postinfection. (A) Cell lines HI-J and
RC-25 have the same surface level of CXCR4, but the CD4 level of HI-J is 15-fold higher
than that of RC-25. (B) The cell surface levels of CD4 are similar between HI-R and RC-49
cells, while the surface level of CXCR4 on RC-49 is six-fold lower than that of HI-R cells.
The standard deviations of three independent experiments are shown in the error bars.
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viruses were lysed after extensive washing and then subjected to a p24
ELISA assay. Two groups of MAbs were used to capture viruses, including
(i) the CD4-independent MAbs: b12 (Fig. 4A), which binds to the CD4-
binding site; 697-30D (Fig. 4B) — the V2 region; F425-B4a1 and 902
(Fig. 4C) — the V3 loop; ID6 and Chessie 6 (Fig. 4D) — the C1 region;
Chessie 13-39.1 (Fig. 4E) — the C2 region; 670-30D (Fig. 4F) — the C5
region, and (ii) the CD4-inducedMAbs: F425A1g8 (Fig. 4G), 17b (Fig. 4H)
and E51 (Fig. 4I) which bind the coreceptor-binding region; and A32
(Fig. 4J)— the C1/C4 region. The MSDmutants L12 and L12G showed an
approximately 2-fold decrease in the binding of antibodies to epitopes in
the V2 and C5 region (MAbs 697-30D and 670-30D), while the mutant
L12G2 showed a WT binding ability to the MAbs in these regions.
Moreover, theMSD “core”mutants resulted in 2- to 4-fold increases in the
binding of MAbs (ID6 and Chessie 6) to epitopes in the C1 region.
Consistent with the conformational changes in the C1 region, the binding
of A32 to its conformational epitope in the C1 and C4 regions also
increased approximately 2-fold. In spite of the conformational changes
observed in the V2, C1, and C5 region, binding of antibodies to the V3 and
C2 regions was not affected by the MSD “core”mutants. In addition, the
accessibility of the MAb b12 to the CD4-binding region and CD4i MAbs
F425a1g8, 17b and E51 to coreceptor-binding regions were not affected
either,which is consistentwith the infectivity data based on the Kabat cell
lines, indicating an intact CD4 binding and coreceptor recognition of the
Env mutants.MSD “core” mutants change the conformation of the gp41 ectodomain
We used the same virus capture assay to examine potential
conformational changes in the gp41 ectodomain. Four anti-gp41
MAbs were used: NC-1 (Fig. 5A) speciﬁcally binds to the six-helix
bundle, T32 (Fig. 5B) to the immunodominant loop in between the
HR1 and HR2 regions, D50 (Fig. 5C) to the HR2 region, and 4E10 to the
MPER region (Fig. 5D). Binding of antibody to the 6-helix bundle in
the mutant L12 decreased to 50% of WT following induction by sCD4,
while the mutants L12G and L12G2 were not signiﬁcantly affected.
Moreover, the exposure of the immunodominant loop was also
reduced in the MSD mutants: L12 43% of WT, L12G 57%, and L12G2
81%, which suggested a stoichiometric relationship between the
conformational changes in the gp41 ectodomain and the number of
substitutions in the MSD “core” region. While the HR2 region of the
MSD “core” mutants was fully accessible to the MAb D50 (Fig. 5C),
exposure of the downstream MPER region, as assayed by MAb 4E10
binding, was decreased in the L12 mutant. These results were
conﬁrmed by immunoprecipitating viral gp41 with the same MAbs
in the presence or absence of sCD4, followed by a western blotting
using the anti-gp41 MAb Chessie 8 (data not shown).
MSD “core” mutants exhibit the same sensitivity to the fusion inhibitors,
T20 and C34, as WT
In order to understand the degree to which the conformation of
the gp41 ectodomain has been changed by the MSD “core” mutants,
we compared sensitivity of the Env mutants to the fusion inhibitors,
C34 and T20, to that of WT. The inhibition kinetics of Env-mediated
cell–cell fusion was measured by treating cells with the fusion
inhibitors in a gradient of concentrations (Fig. 6A and B). The MSD
mutants were as sensitive to either T20 or C34 as WT. Similar results
were observed in the experiment measuring the T20 and C34
inhibition kinetics of viral infectivity (Fig. 6C and D). These data
indicated that alterations in the gp41 ectodomain induced by theMSD
“core” mutants were unlikely to slow formation of the six-helix
bundle once conformational changes were initiated and that access to
the HR1 coiled-coil was retained in the MSD mutants, allowing the
binding of the inhibitor peptides.
Discussion
Previous studies have demonstrated that, in addition to anchoring
the Env in membrane, themembrane-spanning domain of HIV-1 gp41
plays a role in Env incorporation and virus–cell entry during the viral
life cycle (Shang et al., 2008; Yue et al., 2009). The MSD, and in
particular its N-terminal “core” region, is a very highly conserved
region in the Env sequence. We have demonstrated that the most
conserved residue F683 and the GGxxG motif in the MSD “core” are
critical for the virus–cell entry and subsequent viral infectivity by
using a “recovery-of-function” mutagenesis approach (Shang et al.,
2008). Truncation of the cytoplasmic domain of the MSD “core”
mutants was not able to rescue the defect in virus–cell entry. In the
current study, we investigated the molecular basis for the defects in
viral entry observed with the MSD “core” mutants through an
examination of conformational changes in the extracellular domains
of Env, as well as changes in the efﬁciency of virus–cell attachment,
receptor/coreceptor recognition, and membrane fusion.
Virions carrying the MSD “core”mutants all exhibited WT binding
to the surface of target cells at different temperatures, indicating that
substitutions in the MSD “core” regions did not inﬂuence the speciﬁc
virus–cell binding mediated by the interaction of HIV-1 Env with CD4
receptors and chemokine coreceptors on cell surface. Consistent with
this result, we demonstrated that changes in the surface levels of CD4
receptors and CXCR4 coreceptors on target cells gave rise to similar
variations in viral infectivity for theWT and for theMSDmutants. This
Fig. 4. gp120 virus capture assay. Puriﬁed viruses were incubated at 37 °C in 96-well plates which have been precoated with anti-gp120 monoclonal antibodies. The coating
antibodies target to different epitopes of the gp120 glycoprotein: b12 (A) binds to the CD4-binding site, 697-30D (B) to the V2 region, F425 B4a1 and 902 (C) to the V3 loop, ID6 and
Chessie 6 (D) to the C1 region, Chessie 13-39.1 (E) to the C2 region, 670-30D (F) to the C5 region, F425 A1g8 (G), 17b (H) and E51 (I) to the coreceptor-binding region, and A32 (J) to
the C1/C4 region. The bound viruses were lysed in PBS containing 0.5% Triton X-100 and then subjected to a p24 ELISA assay. The experiment was carried out in triplicates for each
antibody and the standard deviation is shown in the error bar.
163L. Shang, E. Hunter / Virology 404 (2010) 158–167result suggested that substitutions in the MSD “core” region did not
affect the utilization of CD4 receptors and CXCR4 coreceptors on cell
surface by HIV-1 Env. Thus, in spite of the alteredMSD “core” region in
the gp41 glycoprotein, the general structure of the Env glycoprotein of
the MSD mutants was retained, and the conformation of the CD4-
binding site and chemokine receptor-binding site remained intact.However, the MSD “core” mutants showed signiﬁcant differences in
the kinetics of cell–cell fusion mediated by HIV-1 Env. This was most
pronounced for L12, which exhibited a clear lag phase prior to
initiation of fusion and a slower rate of increase in the extent of fusion.
The mutants L12G and L12G2 demonstrated intermediate kinetics
between L12 and WT in both the initiation and expansion period of
164 L. Shang, E. Hunter / Virology 404 (2010) 158–167cell–cell fusion. Therefore, the defect in virus–cell entry of the MSD
mutants is most likely due to the impaired kinetics of membrane
fusion mediated by the Env mutants, in particular at the initiation
stage.
The utilization of a panel of MAb in a solid state virus binding assay
allowed us to indirectly probe for changes in the conformation of
gp120 and gp41 by determining whether exposure of a variety of
epitopes had been altered by the MSD mutants. Consistent with the
equivalent entry of all three mutants into cells expressing different
levels of CD4, each mutant bound to the CD4-binding site antibody
b12 similarly to WT. In addition, the regions involved in coreceptor
recognition bound to the CD4 inducible MAbs (F425A1g8, 17b and
E51) at WT levels. However, minor conformational changes, which
were restricted to speciﬁc regions of gp120, were observed in theMSD
mutants. Among all the constant and variable regions of gp120, only
the V2, C1, and C5 regions exhibited altered binding to their cognate
MAbs (697-30D, ID6, Chessie 6, 670-30D), while the remaining
regions in gp120 showed no differences in antibody binding. Since C1
and C5 have been implicated in the non-covalent interactions
between gp120 and gp41, the altered accessibility of these regions
to antibodies could reﬂect a perturbation in the gp120-gp41 interface.
While CD4 induced epitopes in the bridging sheet were presented
equally by the mutants and WT, minor localized conformational
changes were also observed in the gp41 ectodomain of the MSD
mutants by the reductions in the formation of the six-helix bundle
(MAb NC-1) and exposure of the immunodominant loop to MAb T32.
This suggested that even though the open conﬁguration of gp120,
with an exposed bridging sheet, could be stabilized by the binding of
CD4 in the MSDmutants, it was less efﬁcient at inducing downstream
conformational changes in gp41. Moreover, this could result in the lag
phase and slower kinetics of fusion observed for the MSD “core”
mutants. It is difﬁcult to deﬁne quantitatively how the conformational
changes observed above might correlate with the decrease in
fusogenicity. However, one possible interpretation of these results is
that changes in the MSD core alter in a subtle manner the interaction
of gp120 and gp41 in such a way that there is a greater energy barrier
to conformational changes in gp41 induced by CD4 and CXCR4. This
would result in a reduction in overall efﬁciency of the fusion process.
It seems likely, however, that once the conformation change is
initiated it progresses with equivalent kinetics to WT, since all of the
mutants showed similar sensitivity to the fusion inhibitors T20 and
C34, which bind to the trimeric coiled-coil of HR1 and prevent six-
helix bundle formation. Previous studies have shown that reductions
in the kinetics of gp41 conformation changes result in enhanced
inhibition by these fusion inhibitors, and this was not observed with
the MSD “core” mutants. The lack of any evidence for hemifusion
intermediates or defects in fusion pore expansion in these studies,
suggests that the defect in the MSD core mutants is in the initiation of
conformational changes required for fusion rather than at these later
stages of the fusion process. This is consistent with the studies of
Miyauchi et al. (2005), who characterized HIV Env mutants with MSD
replacements in this region (Miyauchi et al., 2005).
How might changes in the amino acid composition of the MSD
“core” induce conformational changes and inhibit processes within
the ectodomain of Env? The highly conserved GGXXG motif in the
HIV-1 MSD “core” region has been postulated to facilitate the
intramembrane helix-helix association by providing a relatively ﬂat
platform for the contact of the three helixes (Russ and Engelman,
2000; Senes et al., 2000). Moreover, residues F683 and V687 are alsoFig. 5. gp41 virus capture assay. Puriﬁed viruses were incubated at 37 °C in 96-well
plates which were precoated with anti-g41 monoclonal antibodies. The coating
antibodies target to different epitopes of the gp41 glycoprotein: NC-1 (A) to the 6-helix
bundles, T32 (B) to the immunodominant loop of gp41 ectodomain, D50 (C) to the HR2
region, and 4E10 (D) to the MPER region. Bound viruses were lysed in PBS containing
0.5% Triton X-100 and then subjected to a p24 ELISA assay. The experiment was carried
out in triplicates for each antibody and the standard deviation is shown in the error bar.
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motif (Unterreitmeier et al., 2007). It is possible that these interac-
tions are optimized to allow some ﬂexibility within the trimer in order
to facilitate conformational changes in gp41. By substituting a stretch
of hydrophobic leucine residues into this region, it is likely that
afﬁnity of both protein–protein and protein–lipid interactions will be
increased, or that the orientation of helixes in the membrane would
be altered. If this resulted in a more rigid trimeric interaction, it could
explain altered interactions with gp120 and the imposition of a
greater energy barrier to gp41 conformational changes, with
subsequent impact on the formation of 6-helix bundles and
membrane fusion.
In summary, the experimental approaches described here have
demonstrated that consistent with its high sequence conservation,
the native MSD “core” amino acid sequence of HIV Env is critical for
efﬁcient membrane fusion during viral infection. Substitutions in the
MSD “core” region reduced the fusogenicity of the Env mainly by
inducing structural changes in the gp41 ectodomain, thereby,
inﬂuencing gp120-gp41 interactions and consequently impairing
initiation of the fusion process.Materials and methods
Cells and antibodies
COS-1, 293T, JC53BL cells and KABAT cell lines were maintained in
complete Dulbecco's modiﬁed Eagle's medium (DMEM) supplemen-
ted with 10% fetal bovine serum and penicillin-streptomycin (all from
Gibco-BRL, Rockville, MD). Cells were grown under conditions of 37 °C
and 5% CO2 in humidiﬁed incubators. The anti-gp120 monoclonal
antibodies b12 (Burton et al., 1994), 697-30D (Zolla-Pazner et al.,
1995), 902 (Chesebro and Wehrly, 1988), F425b4a1, ID6 (Gomez-
Roman et al., 2002), Chessie 6 (Abacioglu et al., 1994), Chessie 13-39.1
(Abacioglu et al., 1994), 670-30D (Zolla-Pazner et al., 1995),
F425a1g8, 17b (Kwong et al., 1998), E51 (Huang et al., 2004), A32
(Wyatt et al., 1995), and anti-gp41monoclonal antibodies NC-1 (Jiang
et al., 1998), T32 (Earl et al., 1997), 4E10 (Stiegler et al., 2001), and
D50 (Earl et al., 1997) along with HIV-1 patient Ig, fusion inhibitors
(T20 and C34) were obtained from the AIDS Research and Reference
Reagent Program, Division of AIDS, National Institute of Allergy and
Infectious Diseases, National Institutes of Health. The pooled HIV-1
patient sera were provided through the Emory CFAR Clinical Core.Virus–cell attachment assay
Viruses were harvested from proviral DNA (NL4-3)-transfected
293T cells and puriﬁed through a 25% sucrose cushion by ultracen-
trifugation. JC53BL indicator cells, which express the CD4 receptor and
coreceptors (CXCR4 and CCR5), were coincubated with the same
amount of viruses (normalized by the amount of p24) at 4 °C, 10 °C,
and 25 °C for 2 h. After extensive wash in PBS to remove unbounded
viruses, cells and bounded viruses were lysed in PBS containing 0.5%
Triton X-100. The amount of viruses in cell lysate was measured by
p24 ELISA.Fig. 6. C34 and T20 inhibition of cell-cell fusion mediated by the Env and viral infection.
293T cells transfected with the Env expression vector, pCDNA3.1, were cocultured with
JC53BL indicator cells. Cell mixtures were incubated for 24 h in the presence of fusion
inhibitors, C34 (A) and T20 (B), at speciﬁc concentrations, and then were subjected to a
luciferase activity assay. JC53BL indicator cells were infected with the p24-normalized
viruses in DMEM containing 1% fetal bovine serum, 80 µg/ml DEAE-Dextran and fusion
inhibitors, C34 (C) and T20 (D), at speciﬁc concentrations. Complete DMEMwas added
following 2 h incubation and cells were analyzed for luciferase activity 48 h
postinfection. Error bars represent standard deviations of at least three independent
experiments.
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MSD mutants were cloned into a proviral vector pTN6-GFP, in
which the nef gene has been replaced by a GFP reporter gene. 293T
cells, which were transfected with these proviral vectors, were
resuspended 48 h posttransfection and were mixed with JC53BL
indicator cells, which had been loaded with ﬂuorescent dye CMAC-
blue (Invitrogen, Carlsbad, CA). The cell mixtures were incubated at
37 °C and 5% CO2 for 0.5, 1, 2, 4, 6, 12, and 24 h. cell–cell fusion was
observed and quantitated by ﬂuorescent microscopy. The rate of cell–
cell fusion was calculated as: (number of fused cells at t2 - number of
fused cells at t1)/(total number of cells)(t2 − t1).
CPZ treatment of cell–cell fusion
HeLa cells were transfected with proviral DNAs (NL4-3). At 48 h
after transfection, cells were cocultured with HeLa P4 indicator cells,
which express the CD4 receptor and CXCR4 coreceptor and also carry
a β-galactosidase reporter gene, at a 1:1 ratio. Cell mixtures were
incubated for 12 h, and then were treated with 0.1 mM chlorprom-
azine (CPZ, in PBS) for 30 s. After extensive wash in PBS, cells were
incubated in complete DMEM for 12 and then subjected to β-Gal
staining. The numbers of blue cells (per well), which were involved
into syncytia, were counted to measure the cell–cell fusogenicity of
Env mutants.
Flow cytometry analysis of cell–cell fusion
HeLa cells were transfectedwith pNL4-3 proviral DNAs (NL4-3). At
48 h after transfection, cells were stained in serum-free DMEM
containing either 5$$$ul/ml DiO loading solution (Invitrogen,
Carlsbad, CA) or Cell Tracker Green CMFDA (Invitrogen, Carlsbad,
CA) for 45 min at 37 °C. HeLa P4 cells were stained in serum-free
DMEM containing either 5ul/ml DiD loading solution (Invitrogen,
Carlsbad, CA) or Cell Tracker Blue CMAC (Invitrogen, Carlsbad, CA) for
45 min at 37 °C. All cells were washed three times in PBS after
incubation and resuspended in PBS containing 1 mM EDTA. To
measure the potential membrane exchange mediated by HIV-1 Env,
HeLa (DiO) cells were mixed with HeLa P4 (DiD) cells; and to observe
Env-mediated cell–cell fusion, HeLa (Green) cells were mixed with
HeLa P4 (Blue) cells. After 6 h coincubation at 37 °C, cells were
resuspended by trypsinization, ﬁxed in 4% paraformaldehyde, and
then subjected to ﬂow cytometry analysis.
Three color microscopy of cell–cell fusion
HeLa cells (2.5×105 cells per well in 6-well plates) were transfected
with pNL4-3 proviral DNAs. At 48 h after transfection, cells were stained
in serum-free DMEM containing 10 mM cytoplasmic dye CMFDA-green
(Invitrogen, Carlsbad, CA) for 45 min at 37 °C, followed by three washes
in serum-free DMEM. HeLa P4 cells (2.5×105 cells per well in six-well
plates) were initially stained with 5 μl/ml DiI loading solution
(Invitrogen, Carlsbad, CA) in serum-free DMEM. Cells were washed
three times in serum-free DMEM after 45 min incubation at 37 °C and
thenwere incubatedwith 10 mMCMAC-blue (Invitrogen, Carlsbad, CA)
in serum-freeDMEM for 45 min, followed bywash in serum-freeDMEM
three times. The transfected HeLa and the double-stained HeLa P4 cells
were both resuspended in PBS containing 1 mM EDTA and then were
mixed (1:1) in complete DMEM. The cell mixtures were cocultured at
37 °C for 3 h. Cell–cell fusion events were observed by ﬂuorescent
microscopy.
Virus capture assay
Viruses were harvested from the supernatant of proviral vector
transfected 293T cells by ultracentrifugation through 25% sucrosecushion. Pelleted virus (in PBS) was added into 96-well plates (10 ng
p24 per well), which had been coated with anti-gp120 and anti-gp41
monoclonal antibodies in 50 mM carbonate/bicarbonate buffer pH
9.6, and then incubated at 37 °C for 2 h. For studies involving CD4-
induced exposure of epitopes, 1 ug/ml sCD4wasmixed with the virus
immediately prior to addition to the wells. Unbound viral particles
were removed by extensive washes in PBS. Bound viruses were lysed
in PBS containing 0.5% Triton X-100 and then subjected to a p24 ELISA
assay.
C34 and T20 inhibition of cell–cell fusion and viral infection
293T cells were transfected with pCDNA3.1 expression vectors,
which also express HIV-1 Tat protein. At 36–48 h after transfection,
cells resuspended by trypsinization were combined with JC53BL
indicator cells at a 5:1 ratio. The JC53BL indicator cells carry a HIV LTR
promoter-driven luciferase reporter gene, which is activated by Tat.
Cell mixtures were incubated for 24 h in the presence of T20 or C34 in
speciﬁc concentrations (0, 0.008, 0.04, 0.2, 1, and 5 μg/ml) before the
analysis of luciferase activity.
Medium from 293T cells transfected with proviral vectors was
harvested 72 h posttransfection, ﬁltered through a 0.45 µm mem-
brane to remove cellular debris, and total virions were quantiﬁed
using a p24 ELISA assay. The p24-normalized virus-containing
supernatant was added to JC53BL indicator cells cultured in DMEM
containing 1% fetal bovine serum, 80 µg/ml DEAE-Dextran and T20 or
C34 in speciﬁc concentrations. Complete DMEM was added following
2 h incubation and cells were analyzed for luciferase activity at 48 h
postinfection.
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